Nusano
  • Company
    • Leadership
    • Mission & Values
    • West Valley City
    • Contact Us
  • Technology
  • Batteries
  • Energy
    • HALEU
    • Nuclear Fuel Cycle
  • Industrial
  • Life Sciences
    • Medical Isotopes
    • Request Quote
    • R&D Collaboration
    • Advisory Board
    • About Nuclear Med
  • News
    • Press Releases
    • Video
    • Podcast
    • Email Sign Up
  • Careers
    • Current Openings
    • Life in Utah
Select Page
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

by Scott Larrivee | Jun 26, 2025 | News

The following is a copy of a press release issued by Cellectar Biosciences Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for...
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

by Scott Larrivee | Apr 17, 2025 | News

The following is a copy of a press release issued by Clarity Pharmaceuticals on April 17, 2025 in Australia. Minor edits have been made in this copy to account for English spelling preferences in the United States. Highlights Clarity has signed a commercial-scale...
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Nusano and GlyTherix Announce Lutetium-177 Supply Agreement

by Scott Larrivee | Dec 9, 2024 | News

VALENCIA, Calif. and SYDNEY, Australia – Dec. 9, 2024 – Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid...
Nusano and Starget Pharma Announce Supply Agreement to Accelerate Smart Targeted Radioligand Development

Nusano and Starget Pharma Announce Supply Agreement to Accelerate Smart Targeted Radioligand Development

by Scott Larrivee | Oct 17, 2024 | News

Image above: Starget Pharma, stargetpharma.com VALENCIA, Calif. and TEL AVIV, Israel – Oct. 17, 2024 – Nusano, a physics company transforming the production of radioisotopes, and Starget Pharma, a clinical-stage biotechnology company developing precision peptide...
Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals

Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals

by Scott Larrivee | Jul 10, 2024 | News

VALENCIA, Calif. and BOCA RATON, Fla. – July 10, 2024 – Nusano Inc. (Nusano), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. (PharmaLogic), a leading radiopharmaceutical contract development and manufacturing...

Recent Posts

  • Nusano Achieves Key Technology Milestone Enabling Simultaneous Production of Multiple Radioisotopes
  • Talk Radioisotopes: Paul Schrimpf, Proprietor & Entrepreneur, Cyrall
  • Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
  • Nusano CEO Chris Lowe on Connor Group Podcast
  • dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

Recent Comments

No comments to show.
Nusano
Supplying the fight against cancer & enabling life-changing innovations
  • Follow
  • Follow
  • Follow
Company
about us
Leadership
Contact us
technology

The Nusano Platform
R&D Collaboration

Resources
News
Careers
Suppliers
© 2025 Nusano | Web design
Privacy Policy – Terms of Service